Brief: Irlab Therapeutics Obtains Patent For Candidate Pirepemat

IRLAB Therapeutics AB

02/09/2021 07:33

Sept 2 (Reuters) - IRLAB Therapeutics AB  IRLABa.ST :
    * IRLAB OBTAINS STRENGTHENED PATENT PROTECTION FOR PHASE II
CANDIDATE PIREPEMAT
    * GRANTED PATENT, US 11,078,158 B2, SPECIFICALLY COVERS A
CHEMICAL
PROCESS FOR MANUFACTURING PIREPEMAT IN ITS PURE FORM
    * HAS BEEN GRANTED A NEW PATENT ON MANUFACTURING PROCESS FOR
DRUG
CANDIDATE PIREPEMAT BY US PATENT OFFICE
    * PIREPEMAT IS ONE OF IRLAB'S CLINICAL DRUG CANDIDATES AND
UNDER
DEVELOPMENT IN PHASE IIB FOR TREATMENT OF IMPAIRED BALANCE AND
FALLS IN PARKINSON'S DISEASE

Source text for Eikon:  ID:nMFN5jv7tZ 
Further company coverage:  IRLABa.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))